Octagam 10% Gains Orphan Drug Status for Rare Muscle, Skin Disorder

Currently, there is no cure for dermatomyositis and its cause is unknown
Currently, there is no cure for dermatomyositis and its cause is unknown

Octapharma announced that Octagam 10% (immune globulin intravenous [human]) Liquid has been granted Orphan Drug Designation to treat dermatomyositis, a rare disorder involving chronic inflammation and degenerative changes of the muscles and skin.

Dermatomyositis primarily presents as a skin rash immediately before or along with progressive muscle weakness. Currently, there is no cure for dermatomyositis and its cause is unknown.  

Related Articles

Octagam 10% is currently approved to treat chronic immune thrombocytopenic purpura (ITP) in adult patients. It is supplied as 2g, 5g, 10g, or 20g single-use bottles. 

For more information call (866) 766-4860 or visit Octapharma.com.